Clinical Trials Logo

Stage II Bladder Cancer AJCC v8 clinical trials

View clinical trials related to Stage II Bladder Cancer AJCC v8.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06350734 Recruiting - Clinical trials for Stage IIIA Bladder Cancer AJCC v8

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Start date: October 12, 2018
Phase:
Study type: Observational

This study evaluates the effect of bladder cancer treatment on quality of life.

NCT ID: NCT06040762 Recruiting - Clinical trials for Stage IIIA Bladder Cancer AJCC v8

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients Receiving Chemotherapy Before Radical Cystectomy, Get Moving Trial

Start date: December 19, 2023
Phase: N/A
Study type: Interventional

Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline. This clinical trial evaluates the utility of a personalized home-based prehabilitation exercise intervention for the improvement of physical function and surgical outcomes in patients receiving chemotherapy before routine radical cystectomy for localized (non-metastatic) muscle-invasive bladder cancer. The exercise intervention includes at-home exercise sessions focused on the improvement of core strength and balance as well as personalized step count goals, delivered to patients remotely via a smart-device-based application (ExerciseRx). Encouraging physical activity before surgery may improve physical function and surgical outcomes in patients who are scheduled to undergo surgery for their non-metastatic muscle-invasive bladder cancer.

NCT ID: NCT05581589 Recruiting - Clinical trials for Stage IIIA Bladder Cancer AJCC v8

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Start date: June 15, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan before radical cystectomy may make the surgery more effective in patients with muscle invasive bladder cancer.

NCT ID: NCT04383743 Recruiting - Clinical trials for Stage IIIA Bladder Cancer AJCC v8

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Start date: November 24, 2020
Phase: Phase 2
Study type: Interventional

This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, adriamycin, and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and combination chemotherapy before surgery may work better in treating patients with these muscle invasive bladder cancer variants compared to chemotherapy alone.